US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

33.36 -3.29 (-8.98%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
News headline image
Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting
From Castle Biosciences, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
Looking Into Castle Biosciences's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Reports Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Prospective, Multicenter Study Demonstrates That DecisionDx®-Melanoma Test Results Can Significantly Reduce the Number of Sentinel Lymph Node Biopsy (SLNB) Procedures Performed When Used Within the Context of Current Guidelines
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023 ↗
 
Via Benzinga
News headline image
Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year
From Castle Biosciences, Inc.
Via Business Wire
News headline image
This Analyst With 90% Accuracy Rate Raises PT On Chesapeake Energy; Here Are 5 Stock Picks For Last Week From Benzinga's Most Accurate Analysts ↗
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
News headline image
This Analyst With 82% Accuracy Rate Boosts PT On Booking Holdings; Here Are 5 Stock Picks For Thursday From Benzinga's Most Accurate Analysts ↗
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes... 
Via Benzinga
News headline image
Castle Biosciences Announces Third Quarter 2022 Results
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Present at Upcoming Investor Conferences
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Real-World Clinical Utility Study Published in Cancer Investigation Demonstrates the Impact of DecisionDx®-SCC Test Results in Guiding Risk-Aligned Care for Patients with Cutaneous Squamous Cell Carcinoma
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program
From Castle Biosciences, Inc.
Via Business Wire
News headline image
New Data Demonstrate that the Utilization of TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus over the Standard of Care Alone
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences Presents New Data Demonstrating the Impact of DecisionDx®-SCC Test Results on the Management of Medicare-Eligible Patients with Cutaneous Squamous Cell Carcinoma and One or More Risk Factors
From Castle Biosciences, Inc.
Via Business Wire
News headline image
New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2
From Castle Biosciences, Inc.
Via Business Wire
News headline image
Results from a Randomized Controlled Trial Show That TissueCypher® Barrett’s Esophagus Test Results Can Significantly Improve the Accuracy of Risk Assessments and Adherence to Guideline-Recommended Patient Management
From Castle Biosciences, Inc.
Via Business Wire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >